In a multicenter neoadjuvant study, GETN(A)-1, 70 patients with HER2-positive stage II/III operable breast cancer received docetaxel (75 mg/m2) and carboplatin [area under curve (AUC) of 6] every 3 weeks plus weekly trastuzumab (initial dose 4 mg/kg, followed by 2 mg/kg). The gene discussed is ERBB2; the disease is breast carcinoma.